Home » Multiple Trial Designs, Endpoints May Be Best for CF Treatments
Multiple Trial Designs, Endpoints May Be Best for CF Treatments
No one trial design or endpoint is optimal for inhaled antibiotics for cystic fibrosis (CF) patients infected with a chronic bacterial infection. But any clinical trial of a treatment for CF patients infected with Pseudomonas aeruginosa should show superiority rather than noninferiority, Bruce Montgomery, a senior adviser at Gilead Sciences, said at a recent FDA workshop on developing trial designs for aerosolized antibiotics to treat CF patients.
Clinical Trials Advisor
Clinical Trials Advisor
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May